|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZCCHC24 |
Gene summary for ZCCHC24 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZCCHC24 | Gene ID | 219654 |
| Gene name | zinc finger CCHC-type containing 24 | |
| Gene Alias | C10orf56 | |
| Cytomap | 10q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024QZP0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 219654 | ZCCHC24 | male-WTA | Human | Thyroid | PTC | 5.28e-16 | 1.79e-01 | 0.1037 |
| 219654 | ZCCHC24 | PTC04 | Human | Thyroid | PTC | 1.82e-12 | 1.57e-01 | 0.1927 |
| 219654 | ZCCHC24 | PTC05 | Human | Thyroid | PTC | 4.49e-05 | 2.21e-01 | 0.2065 |
| 219654 | ZCCHC24 | PTC07 | Human | Thyroid | PTC | 3.03e-05 | 1.46e-01 | 0.2044 |
| 219654 | ZCCHC24 | ATC09 | Human | Thyroid | ATC | 7.85e-05 | 1.47e-01 | 0.2871 |
| 219654 | ZCCHC24 | ATC12 | Human | Thyroid | ATC | 2.64e-19 | 4.79e-01 | 0.34 |
| 219654 | ZCCHC24 | ATC13 | Human | Thyroid | ATC | 8.39e-62 | 1.22e+00 | 0.34 |
| 219654 | ZCCHC24 | ATC1 | Human | Thyroid | ATC | 1.08e-04 | 1.62e-01 | 0.2878 |
| 219654 | ZCCHC24 | ATC2 | Human | Thyroid | ATC | 1.92e-03 | 7.32e-01 | 0.34 |
| 219654 | ZCCHC24 | ATC3 | Human | Thyroid | ATC | 2.34e-05 | 3.57e-01 | 0.338 |
| 219654 | ZCCHC24 | ATC4 | Human | Thyroid | ATC | 7.43e-25 | 5.74e-01 | 0.34 |
| 219654 | ZCCHC24 | ATC5 | Human | Thyroid | ATC | 1.50e-78 | 1.31e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZCCHC24 | SNV | Missense_Mutation | novel | c.550T>A | p.Ser184Thr | p.S184T | Q8N2G6 | protein_coding | deleterious(0.02) | probably_damaging(0.982) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZCCHC24 | SNV | Missense_Mutation | novel | c.14C>T | p.Ser5Leu | p.S5L | Q8N2G6 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.885) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| ZCCHC24 | SNV | Missense_Mutation | c.675N>G | p.His225Gln | p.H225Q | Q8N2G6 | protein_coding | deleterious(0.05) | possibly_damaging(0.796) | TCGA-AA-A01T-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| ZCCHC24 | SNV | Missense_Mutation | novel | c.340N>T | p.Asp114Tyr | p.D114Y | Q8N2G6 | protein_coding | deleterious(0) | possibly_damaging(0.75) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZCCHC24 | SNV | Missense_Mutation | rs776883202 | c.505N>A | p.Glu169Lys | p.E169K | Q8N2G6 | protein_coding | deleterious(0.04) | probably_damaging(0.952) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| ZCCHC24 | SNV | Missense_Mutation | c.634N>A | p.Gly212Ser | p.G212S | Q8N2G6 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZCCHC24 | SNV | Missense_Mutation | novel | c.367N>G | p.Lys123Glu | p.K123E | Q8N2G6 | protein_coding | deleterious(0) | benign(0.152) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| ZCCHC24 | SNV | Missense_Mutation | novel | c.562N>T | p.Met188Leu | p.M188L | Q8N2G6 | protein_coding | deleterious(0.02) | possibly_damaging(0.833) | TCGA-44-7661-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ZCCHC24 | SNV | Missense_Mutation | rs745523487 | c.635G>T | p.Gly212Val | p.G212V | Q8N2G6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ZCCHC24 | SNV | Missense_Mutation | rs770473495 | c.493N>T | p.Arg165Cys | p.R165C | Q8N2G6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-77-6844-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |